Seeing Is Believing
Currently out of the existing stock ratings of Brian Cheng, 58 are a BUY (74.36%), 17 are a HOLD (21.79%), 3 are a SELL (3.85%).
Analyst Brian Cheng, currently employed at JPMORGAN, carries an average stock price target met ratio of 42.08% that have a potential upside of 16.91% achieved within 72 days.
Brian Cheng’s has documented 151 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ZYME, Zymeworks Common Stock at 15-Oct-2025.
Analyst best performing recommendations are on CRGX (CARGO THERAPEUTICS, COMMON STOCK).
The best stock recommendation documented was for PTGX (PROTAGONIST THERAPEUTICS) at 3/4/2025. The price target of $57 was fulfilled within 7 days with a profit of $18.34 (47.44%) receiving and performance score of 67.77.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$42
$21.34 (103.29%)
$45
2 months 11 days ago
(11-Aug-2025)
0/3 (0%)
$27.11 (182.07%)
Buy
$49
$28.34 (137.17%)
$47
2 months 11 days ago
(11-Aug-2025)
4/10 (40%)
$34.11 (229.08%)
195
Buy
$35
$14.34 (69.41%)
$32
3 months 21 days ago
(01-Jul-2025)
0/2 (0%)
$21.38 (156.98%)
Buy
$45
5 months 10 days ago
(12-May-2025)
0/5 (0%)
$35.65 (381.28%)
Buy
$60
6 months 13 days ago
(09-Apr-2025)
14/33 (42.42%)
$45.45 (312.37%)
165
Which stock is Brian Cheng is most bullish on?
Which stock is Brian Cheng is most reserved on?
What Year was the first public recommendation made by Brian Cheng?